Purnanand Sarma elected to serve as 14th TiE Boston President The president-elect will begin his term on July 01, 2024, following six months of working closely with current President Yash Shah.

Purnanand Sarma Ex-Board Member, President & CEO, Immunome Ex-Board Member, President & CEO, Taris Biomedical LinkedIn

Dr. Purnanand Sarma, until most recently, served as President, CEO and Board Member of Immunome (NASDAQ:IMNM), which he successfully led through an IPO in 2020, a large pharma transaction with $2B+ potential in January 2023, and a merger bringing in a seasoned new CEO and a $125M concurrent investment in October 2023.    He has 30+ years of experience in all aspects of pharmaceutical and biotechnology business across multiple therapeutic platforms, and in companies of various sizes ranging from start-ups to large cap pharmaceutical companies.  In addition to conceiving and developing drugs that are commercially sold or in clinical development, Sarma transacted several multi-hundred million products/assets focused on areas of high clinical need and raised over $250M in private and public equity markets. Prior to Immunome, Sarma was the CEO and Board member of TARIS Biomedical (acquired by J&J) where the product he developed for bladder cancer, currently in late stage clinical testing at J&J, is projected to be a $5B+ product.  Sarma was VP and General Manager of World-wide Drug Delivery Technologies for Cephalon Corporation (NYSE:CEPH) and spent nearly 10 years at Nektar Therapeutics (NASDAQ:NKTR), working across inhalation, conjugation and multiple powder technology platforms He started his career at SmithKline Beecham in King of Prussia, PA after obtaining his PhD in Pharmaceutics from the University of Minnesota and B.Pharm from Andhra University, Visakhapatnam, India. He credits his success to keeping the patient as the focal point of inspiration.

|